Form 8-K - Current report:
SEC Accession No. 0001628280-21-023371
Filing Date
2021-11-15
Accepted
2021-11-15 16:11:07
Documents
12
Period of Report
2021-11-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 8-K xfor-20211115.htm   iXBRL 8-K 36516
  Complete submission text file 0001628280-21-023371.txt   183053

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20211115.xsd EX-101.SCH 1914
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20211115_lab.xml EX-101.LAB 25998
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20211115_pre.xml EX-101.PRE 13731
5 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20211115_htm.xml XML 12212
Mailing Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134
Business Address 61 NORTH BEACON STREET 4TH FLOOR BOSTON MA 02134 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38295 | Film No.: 211410623
SIC: 2836 Biological Products, (No Diagnostic Substances)